Cascara sagrada laxatives
This article was originally published in The Tan Sheet
Executive Summary
CDER Ombudsman James Morrison should "intercede and facilitate" a meeting between AHPA, Division of OTC Drug Products to discuss data on cascara sagrada, trade group says in Sept. 12 letter. OTC division denied association's earlier request to discuss May 9 final rule classifying ingredient as Category II in OTC laxative products. AHPA also has asked FDA to stay rule's Nov. 5 effective date (1"The Tan Sheet" June 17, 2002, p. 7). Separate petition submitted by Arnall Golden & Gregory (Atlanta) requests that FDA withhold enforcement action against manufacturers of cascara sagrada laxatives pending publication of laxatives final monograph. Petition also suggests FDA could consider "imposing certain labeling restrictions relating to the product's use" to keep such laxatives on the market...
You may also be interested in...
Aloe Definition Clarification In Laxatives Final Rule Requested By AHPA, IASC
FDA's final rule on aloe and cascara sagrada does not properly distinguish between aloe used in OTC drug laxatives and aloe vera gel used in foods and dietary supplements, AHPA and the International Aloe Science Council say in a 1citizen petition
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.